{
  "report_rows": [
    {
      "kpi": "Adjusted diluted EPS (fiscal 2026 Q3)",
      "prediction": "BEAT",
      "answer": "pred ~$4.42 vs. cons $4.35",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue (fiscal 2026 Q3)",
      "prediction": "MISS",
      "answer": "pred ~$83.2B vs. cons $84.1B",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. Healthcare Solutions segment operating income (fiscal 2026 Q3)",
      "prediction": "BEAT",
      "answer": "pred ~$980M vs. cons $965M",
      "confidence": "LOW"
    }
  ],
  "guide_rows": [
    {
      "kpi": "Adjusted diluted EPS",
      "prediction": "BETTER",
      "answer": "guide ~$17.83 vs. cons $17.79 (fiscal 2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Revenue growth",
      "prediction": "LOWER",
      "answer": "guide ~4.5% vs. cons 4.9% (fiscal 2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "U.S. Healthcare Solutions operating-income growth",
      "prediction": "UNCHANGED",
      "answer": "guide ~15.0% vs. cons 15.0% (fiscal 2026 midpoint)",
      "confidence": "MEDIUM"
    },
    {
      "kpi": "Adjusted free cash flow",
      "prediction": "UNCHANGED",
      "answer": "guide ~$3.0B vs. cons $3.0B (fiscal 2026)",
      "confidence": "MEDIUM"
    }
  ],
  "day1_residual_pct": 2.4,
  "day1_confidence": "MEDIUM",
  "day5_residual_pct": 3.1,
  "day5_path": "FOLLOW-THROUGH",
  "day5_rationale": "The predicted fiscal 2026 EPS-guide midpoint of ~$17.83 versus consensus of $17.79, combined with predicted Q3 EPS of ~$4.42, implies fiscal Q4 EPS of roughly $4.58 versus consensus near $4.53. That modestly positive out-period math should support upward revisions after the initial relief rally, while the revenue-guide reduction is likely discounted as predominantly low-margin mix pressure.",
  "day5_confidence": "MEDIUM"
}